Comparison timestamp: 2025-05-05 14:38:12 UTC
RestoredCDC URL: http://restoredcdc.org/www.cdc.gov/niosh-rtecs/WS7D80E8.html
Live cdc.gov URL ↗: https://www.cdc.gov/niosh-rtecs/WS7D80E8.html
RestoredCDC URL: http://restoredcdc.org/www.cdc.gov/niosh-rtecs/WS7D80E8.html
Live cdc.gov URL ↗: https://www.cdc.gov/niosh-rtecs/WS7D80E8.html
Removed: Line removed from cdc.gov. Specific word removals are highlighted.
Added: Line added to cdc.gov. Specific word additions are highlighted.
Injected:
Line or disclaimer added by RestoredCDC.org.
Unchanged: Line unchanged.
Original site: www.cdc.gov/niosh-rtecs/WS7D80E8.html | RestoredCDC.org is an independent project, not affiliated with CDC or any federal entity. Visit CDC.gov for free official information. Due to archival on January 6, 2025, recent outbreak data is unavailable. Videos are not restored. Access data.restoredcdc.org for restored data. Use of this site implies acceptance of this disclaimer.[More]About Us Report Bug Compare ContentSkip directly to page optionsThe National Institute for Occupational Safety and Health (NIOSH)Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting PeopleSearchSearch Menu Navigation Menu× NIOSHNIOSH All CDCSubmit* Licensing Agreement Signed for RTECS* How Do I Access the RTECS Database?* Features of the RTECS Database* The National Institute for Occupational Safety and Health (NIOSH) HomeThe National Institute for Occupational Safety and Health (NIOSH)1. Registry of Toxic Effects of Chemical Substances (RTECS)Sulfuric acid, dimethyl esterRelated PagesRTECS #WS8225000CAS #77-78-1See: NMAM or OSHA MethodsUpdatedMarch 2019Molecular Weight126.14Molecular FormulaC2H6O4SSynonymsDimethyl monosulfateDimethyl sulfateDimethyl sulfate (ACGIH:OSHA)Dimethyl sulphateDimethylester kyseliny sirove (Czech)Dimethylsulfaat (Dutch)Dimethylsulfat (Czech)Dimetilsolfato (Italian)DMS (methyl sulfate)Dwumetylowy siarczan (Polish)Methyl sulfateMethyle (sulfate de) (French)RCRA waste number U103Sulfate de methyle (French)Sulfate dimethylique (French)Skin and Eye Irritation and ReferencesRoute/Organism Dose Effect Referenceeye /rabbit 100 mg/4S rinse severe FCTOD7 20,573,1982eye /rabbit 50 µg/24H severe 85JCAE -,1079,1986skin /rabbit 10 mg/24H open irritation test severe AMIHBC 4,119,1951Mutation Data and ReferenceSystem Test Route/Organism/Tissue Dose Referencebody fluid assay ovary/rat 300 mg/kg MUREAV 143,263,1985Cytogenetic Analysis intraperitoneal/rat 350 mg/kg NASLDX 3,187,1980Cytogenetic Analysis inhalation/rat 290 µg/m3/16W GTPZAB 30(9),38,1986Cytogenetic Analysis unreported route/human 2 mg/m3 MUREAV 147,301,1985Cytogenetic Analysis inhalation/mouse 240 µg/m3/10W GTPZAB 30(9),38,1986Cytogenetic Analysis Ascites tumor/mouse 10 mmol/L BIZNAT 88,49,1970Cytogenetic Analysis lung/hamster 50 µmol/L CRNGDP 3,385,1982DNA adduct Ascites tumor/mouse 5 µmol/L MUREAV 89,95,1981DNA adduct intraperitoneal/mouse 30 mg/kg CALEDQ 146,155,1999DNA adduct inhalation/rat 0.1 ppm/6H INHTE5 16,581,2004DNA adduct HeLa cell/human 5 µmol/L MUREAV 89,95,1981DNA adduct /Escherichia coli 5 µmol/L MUREAV 89,95,1981DNA Damage /Other microorganisms 100 mmol/L CBINA8 14,101,1976DNA Damage /Other microorganisms 200 mg/L CBINA8 13,151,1976DNA Damage /Bacillus subtilis 130 mmol/L MUREAV 9,141,1970DNA Damage lymphocyte/human 1 mmol/L JACTDZ 1(3),125,1982DNA Damage fibroblast/human 100 µmol/L CRNGDP 4,559,1983DNA Damage liver/rat 100 µmol/L/3H MUREAV 629,49,2007DNA Damage /Saccharomyes cerevisiae 13.3 mg/L/17H MUREAV 633,80,2007DNA Damage intraperitoneal/mouse 100 mg/kg MUREAV 467,83,2000DNA Damage intravenous/rat 80 mg/kg MUREAV 75,63,1980DNA Damage liver/rat 30 µmol/L MUREAV 189,69,1987DNA Damage inhalation/mouse 20 µg/kg PCBPBS 6,101,1976DNA Damage lung/hamster 800 µmol/L/1H-continuous CRNGDP 1,795,1980DNA inhibition oral/mouse 20 gm/kg ARGEAR 51,605,1981DNA inhibition intraperitoneal/mouse 100 mg/kg MUREAV 46,305,1977DNA inhibition HeLa cell/human 2 mmol/L MUREAV 92,427,1982DNA inhibition fibroblast/human 75 µmol/L CRNGDP 4,559,1983DNA repair /Escherichia coli 331 µmol/L MUREAV 272,145,1992DNA repair /Other microorganisms 640 µg/plate BIZNAT 95,463,1976gene conversion and mitotic recombination /Saccharomyes cerevisiae 1900 µmol/L SOGEBZ 17,915,1981host-mediated assay Salmonella typhimurium/mouse 2500 µmol/kg CBINA8 19,241,1977micronucleus test ovary/hamster 58.5 mg/L/24H MUREAV 633,80,2007micronucleus test intraperitoneal/mouse 12500 µg/kg/48H- intermittent MUREAV 389,3,1997mutation in mammalian somatic cells ovary/hamster 20 µmol/L MUREAV 57,217,1978mutation in mammalian somatic cells lung/hamster 1 mg/L/1H CRNGDP 1,175,1980mutation in microorganisms /Schizosaccharomyces pombe 590 µmol/L (-enzymatic activation step) CBINA8 14,195,1976mutation in microorganisms /Neurospora crassa 1000 ppm/13M (-enzymatic activation step) GENTAE 67,189,1971mutation in microorganisms /Saccharomyes cerevisiae 500 ppm/12M (-enzymatic activation step) GENTAE 78,1101,1974mutation in microorganisms /Other microorganisms 1000 ppm/13M (-enzymatic activation step) GENTAE 67,189,1971mutation in microorganisms /Other microorganisms 250 ppm (-enzymatic activation step) SOGEBZ 8,412,1972mutation in microorganisms /Other microorganisms 2 mmol/L (-enzymatic activation step) HEREAY 46,279,1960mutation in microorganisms /Salmonella typhimurium 10 µmol/plate (+enzymatic activation step) CBINA8 19,241,1977mutation in microorganisms /Salmonella typhimurium 4300 nmol/L/1H (-enzymatic activation step) PNASA6 75,4465,1978mutation in microorganisms /Escherichia coli 20 µmol/L (-enzymatic activation step) ARTODN 46,277,1980other mutation test systems /Escherichia coli 2 nmol/tube PNASA6 79,5971,1982other mutation test systems /Salmonella typhimurium 38 mg/L MUREAV 192,239,1987other mutation test systems /Other microorganisms 100 mmol/L CBINA8 14,101,1976phage inhibition capacity /Escherichia coli 65 mmol/L PRLBA4 150,497,1959sex chromosome loss and nondisjunction oral/Drosophila melanogaster 3800 µmol/L NATUAS 203,1404,1964sister chromatid exchange lung/hamster 10 µmol/L CRNGDP 3,385,1982sister chromatid exchange fibroblast/human 1 µmol/L MUREAV 75,63,1980specific locus test oral/Drosophila melanogaster 5 mmol/L MUREAV 182,243,1987Unscheduled DNA Synthesis lymphocyte/human 10 µmol/L CRNGDP 13,1285,1992Unscheduled DNA Synthesis fibroblast/human 50 µmol/L CRNGDP 4,559,1983Unscheduled DNA Synthesis HeLa cell/human 400 µmol/L MUREAV 139,155,1984Unscheduled DNA Synthesis lung/hamster 40 mg/L CBINA8 15,117,1976Unscheduled DNA Synthesis liver/rat 100 µmol/L ENMUDM 3,11,1981Reproductive Effects Data and ReferencesRoute/Organism Dose Effect Referenceintravenous/rat 100 mg/kg (15D pregnant) Reproductive: Effects on embryo or fetus: Fetal death IARCCD 4,45,1973Tumorigenic Data and ReferencesRoute/Organism Dose Effect ReferenceTumorigenic: Equivocal tumorigenic agent by RTECS criteriainhalation/rat lowest published toxic concentration: 17 mg/m3/19W- intermittent Olfaction: Tumors ZEKBAI 74,241,1970Blood: Lymphoma including Hodgkin's diseaseTumorigenic: Carcinogenic by RTECS criteriaintravenous/rat lowest published toxic dose: 20 mg/kg (15D pregnant) Reproductive: Tumorigenic effects: Transplacental tumorigenesis IARCCD 4,45,1973Brain and Coverings: TumorsTumorigenic: Equivocal tumorigenic agent by RTECS criteriasubcutaneous/rat lowest published toxic dose: 50 mg/kg ZEKBAI 74,241,1970Tumorigenic: Tumors at site of applicationAcute Toxicity Data and ReferencesRoute/Organism Dose Effect ReferenceIn Vitro/Human, monocyte Inhibitor Concentration (20 percent kill): 78 µmol/L/24H In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. TOLED5 199,51,2010In Vitro/Human, monocyte Inhibitor Concentration (20 percent kill): 78 µmol/L/2H In Vitro Toxicity Studies: Other assays TOLED5 199,51,2010inhalation/guinea pig lethal concentration (50 percent kill): 32 ppm/1H 85JCAE -,1079,1986inhalation/human Lowest published lethal concentration: 97 ppm/10M 34ZIAG -,226,1969Olfaction: Other olfaction effectsinhalation/mouse lethal concentration (50 percent kill): 280 mg/m3 Behavioral: Somnolence (general depressed activity) GTPZAB 23(3),28,1979Lung, Thorax, or Respiration: Respiratory depressionLung, Thorax, or Respiration: Dyspneainhalation/rat lethal concentration (50 percent kill): 45 mg/m3/4H Lung, Thorax, or Respiration: Cyanosis GTPZAB 24(11),55,1980Blood: Hemorrhageintravenous/rabbit lowest published lethal dose: 50 mg/kg Behavioral: Muscle contraction or spasticity AEXPBL 47,113,1902oral/mouse lethal dose (50 percent kill): 140 mg/kg GTPZAB 23(3),28,1979oral/rabbit lowest published lethal dose: 45 mg/kg Behavioral: Food intake (animal) AEXPBL 47,113,1902oral/rat lethal dose (50 percent kill): 205 mg/kg GTPZAB 23(3),28,1979Behavioral: Muscle contraction or spasticitysubcutaneous/rabbit lowest published lethal dose: 53 mg/kg AEXPBL 47,113,1902Skin: After systemic exposure: Dermatitis, othersubcutaneous/rat lethal dose (50 percent kill): 100 mg/kg ZEKBAI 74,241,1970Other Multiple Dose Data and ReferencesRoute/Organism Dose Effect Referenceinhalation/rat lowest published toxic concentration: 1.5 ppm/5D- intermittent Nutritional and Gross Metabolic: Weight loss or decreased weight gain INHTE5 16,581,2004Olfaction: Ulcerated nasal septuminhalation/rat lowest published toxic concentration: 0.7 ppm/2W- intermittent Olfaction: Other olfaction effects INHTE5 16,581,2004Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammationReviewsOrganization Standard ReferenceAmerican Conference of Governmental Industrial Hygienists (ACGIH) Threshold Limit Value-time-weighted average 0.1 ppm (skin) DTLVS* TLV/BEI,2013American Conference of Governmental Industrial Hygienists (ACGIH) Threshold Limit Value-Confirmed animal carcinogen DTLVS* TLV/BEI,2013International Agency for Research on Cancer (IARC) Cancer Review:Animal Sufficient Evidence IMEMDT 4,271,1974International Agency for Research on Cancer (IARC) Cancer Review:Animal Sufficient Evidence IMEMDT 71,575,1999International Agency for Research on Cancer (IARC) Cancer Review:Human Inadequate Evidence IMEMDT 4,271,1974International Agency for Research on Cancer (IARC) Cancer Review:Human Inadequate Evidence IMEMDT 71,575,1999International Agency for Research on Cancer (IARC) Cancer Review:Group 2A IMEMDT 71,575,1999TOXICOLOGY REVIEW 85CVA2 5,63,1970TOXICOLOGY REVIEW MUREAV 543,201,2003TOXICOLOGY REVIEW CHHSA* 9,6,2002TOXICOLOGY REVIEW FCTOD7 44,1699,2006TOXICOLOGY REVIEW MUREAV 721,27,2011TOXICOLOGY REVIEW MUTAEX 25,3,2010TOXICOLOGY REVIEW MUREAV 763,294,2015TOXICOLOGY REVIEW RTOPDW 54,247,2009TOXICOLOGY REVIEW MUTAEX 33,179,2018Standards and RegulationsOrganization Standard ReferenceMine Safety and Health Administration (MSHA) STANDARD-air time-weighted average 1 ppm (5 mg/m3) (skin) DTLVS* 3,92,1971Occupational Exposure Limit IN ARGENTINA, BULGARIA, COLOMBIA, JORDAN check ACGIH TLV;Occupational Exposure Limit IN SINGAPORE, VIETNAM check ACGIH TLVOccupational Exposure Limit-AUSTRALIA time-weighted average 0.1 ppm (0.52 mg/m3), Carcinogen, JUL2008Occupational Exposure Limit-AUSTRIA TRK-TMW 0.02 ppm (0.1 mg/m3);KZW 0.08 ppm (0.4 mg/m3), skin, production, 2007Occupational Exposure Limit-AUSTRIA TRK-TMW 0.04 ppm (0.2 mg/m3);KZW 0.16 ppm (0.8 mg/m3), skin, use and handl, 2007Occupational Exposure Limit-BELGIUM time-weighted average 0.1 ppm (0.53 mg/m3), Skin, Carcinogen, MAR2002Occupational Exposure Limit-DENMARK time-weighted average 0.01 ppm (0.05 mg/m3), skin, carc, MAY2011Occupational Exposure Limit-FINLAND short term exposure limit 0.01 ppm (0.052 mg/m3), skin, NOV2011Occupational Exposure Limit-FRANCE VME 0.1 ppm (0.5 mg/m3), C2 Carcinogen, FEB2006Occupational Exposure Limit-HUNGARY ceiling concentration 0.1 mg/m3, Skin, Carcinogen, SEP2000Occupational Exposure Limit-ICELAND time-weighted average 0.01 ppm (0.05 mg/m3), carc, skin, NOV2011Occupational Exposure Limit-JAPAN Occupational Exposure Limit 0.1 ppm (0.52 mg/m3), skin, 2A carc, MAY2012Occupational Exposure Limit-KOREA time-weighted average 0.1 ppm (0.5 mg/m3), skin, 2006Occupational Exposure Limit-MEXICO time-weighted average 0.1 ppm (0.52 mg/m3), 2004Occupational Exposure Limit-NEW ZEALAND time-weighted average 0.05 ppm (0.26 mg/m3), skin, JAN2002Occupational Exposure Limit-NORWAY time-weighted average 0.01 ppm (0.05 mg/m3), JAN1999Occupational Exposure Limit-PERU time-weighted average 0.1 ppm (0.52 mg/m3), JUL2005Occupational Exposure Limit-POLAND MAC(time-weighted average) 0.5 mg/m3, MAC(short term exposure limit) 1 mg/m3, JAN1999Occupational Exposure Limit-RUSSIA short term exposure limit 0.1 mg/m3, Skin, JUN2003Occupational Exposure Limit-SWEDEN Group B Carcinogen, JUN2005Occupational Exposure Limit-SWITZERLAND MAK-week 0.02 ppm (0.1 mg/m3), carc 2, skin, JAN2011Occupational Exposure Limit-TURKEY time-weighted average 0.1 ppm (0.5 mg/m3), Skin, JAN1993Occupational Exposure Limit-UNITED KINGDOM time-weighted average 0.05 ppm (0.26 mg/m3), skin, OCT2007Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Construction) 8H time-weighted average 1 ppm (5 mg/m3) (skin) CFRGBR 29,1926.55,1994Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Federal Contractors) 8H time-weighted average 1 ppm (5 mg/m3) (skin) CFRGBR 41,50-204.50,1994Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (General Industry) 8H time-weighted average 1 ppm (5 mg/m3) (skin) CFRGBR 29,1910.1000,1994Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Shipyards) 8H time-weighted average 1 ppm (5 mg/m3) (skin) CFRGBR 29,1915.1000,1993NIOSH Documentation and SurveillanceOrganization Standard ReferenceNational Institute for Occupational Safety and Health (NIOSH) Recommended Exposure Level TO DIMETHYL SULFATE-air 8H Carcinogen time-weighted average 0.1 ppm (Sk) NIOSH* DHHS #92-100,1992National Occupational Exposure Survey 1983 Hazard Code 26880; Number of Industries 5; Total Number of Facilities 185; Number of Occupations 23; Total Number of Employees Exposed 10481; Total Number of Female Employees Exposed 2455National Occupational Hazard Survey 1974 Hazard Code 26880; Number of Industries 3; Total Number of Facilities 83; Number of Occupations 5; Total Number of Employees Exposed 1249Status in Federal AgenciesOrganization ReferenceEPA GENETOX PROGRAM 1988, Inconclusive: Histidine reversion-Ames testEPA GENETOX PROGRAM 1988, Negative: D melanogaster-partial sex chrom. lossEPA GENETOX PROGRAM 1988, Positive/dose response: In vitro SCE-humanEPA GENETOX PROGRAM 1988, Positive: Aspergillus-forward mutation; Carcinogenicity-mouse/ratEPA GENETOX PROGRAM 1988, Positive: D melanogaster-reciprocal translocationEPA GENETOX PROGRAM 1988, Positive: D melanogaster-whole sex chrom. lossEPA GENETOX PROGRAM 1988, Positive: Host-mediated assay; E coli polA without S9EPA GENETOX PROGRAM 1988, Positive: In vitro cytogenetics-nonhumanEPA GENETOX PROGRAM 1988, Positive: In vitro SCE-nonhuman; D melanogaster Sex-linked lethalEPA GENETOX PROGRAM 1988, Positive: S cerevisiae-reversion; S pombe-reversionEPA TSCA 8(a) PRELIMINARY ASSESSMENT INFORMATION, FINAL RULE FEREAC 47,26992,82EPA TSCA Section 8(b) CHEMICAL INVENTORYEPA TSCA Section 8(d) unpublished health/safety studiesEPA TSCA TEST SUBMISSION (TSCATS) DATA BASE, JANUARY 2001NIOSH Analytical Method, 1994: Dimethyl sulfate, 2524NTP 14th Report on Carcinogens,2016:Reasonably anticipated to be human carcinogenOn EPA IRIS databasePage last reviewed: November 16, 2018Content source: National Institute for Occupational Safety and Health* SyndicateRegistry of Toxic Effects of Chemical Substances (RTECS)* Licensing Agreement Signed for RTECS* How Do I Access the RTECS Database?* Features of the RTECS DatabaseFollow NIOSH* YouTubeNIOSH Homepage* Workplace Safety & Health Topics* Publications and Products* Programs* Contact NIOSH* About CDC* Contact Us* 800-232-4636Facebook Twitter Instagram LinkedIn Youtube Pinterest SnapchatFacebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat RSS* CONTACT CDCContact UsCall 800-232-4636Email Us* ABOUT CDC+ About CDC+ Jobs+ Funding* POLICIES+ Accessibility+ External Links+ Privacy+ Policies+ Web Policies+ No Fear Act+ FOIA+ OIG+ No Fear Act+ Nondiscrimination+ Vulnerability Disclosure Policy+ CDC Archive+ Public Health Publications+ HHS.gov+ USA.gov* CONNECT WITH US+ Youtube+ Snapchat* LANGUAGES+ Español+ 繁體中文+ Tiếng Việt+ 한국어+ Tagalog+ Русский+ العربية+ Kreyòl Ayisyen+ Français+ Polski+ Português+ Italiano+ Deutsch+ 日本語+ فارسی+ English* U.S. Department of Health & Human Services* Accessibility* External Links* Privacy* Policies* Web Policies* FOIA* OIG* No Fear Act* FOIA* Nondiscrimination* OIG* Vulnerability Disclosure Policy* CDC Archive* Public Health Publications* HHS.gov* USA.govContent Credential×This image was edited or created using GenAI (generative artificial intelligence).Our experts review all images in an effort to ensure accuracy and quality before use.Learn more about CDC's usage of GenAI.Exit Notification/Disclaimer PolicyCloseLinks with this icon indicate that you are leaving the CDC website.* The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.* Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.* You will be subject to the destination website's privacy policy when you follow the link.* CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.For more information on CDC's web notification policies, see Website Disclaimers.Cancel Continue
Note: Comparison ignores leading/trailing whitespace
and certain script/tracking codes. Word-level
highlighting (optional above) only applies to changed
lines.